Podcast: Look Ahead To PCSK9 Inhibitors With “The Pink Sheet” DAILY Editors
This article was originally published in The Pink Sheet Daily
Executive Summary
Editors provide background on the PCSK9 inhibitor class of biologics that are nearing FDA approval, including FDA advisory committee reviews, commercialization plans and concerns about cost from payers.